Prolonged administration of FTY720 does not cause renal toxicity in mice

被引:9
作者
Galvao, VR
Ginoza, M
Franco, M
Burdmann, EA
Bueno, V
机构
[1] Sao Jose Rio Preto Med Sch, Expt Lab Nefrol, BR-15091128 Sao Paulo, Brazil
[2] Sao Paulo Fed Sch, Sao Paulo, Brazil
[3] Sao Paulo Med Sch, Pathol Lab, Sao Paulo, Brazil
[4] Sao Jose Rio Preto Med Sch, Immunol Lab, BR-15091128 Sao Paulo, Brazil
关键词
D O I
10.1016/j.transproceed.2004.12.300
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Prevention of allograft rejection without renal toxicity caused by calcineurin-inhibitor immunosuppression is a major goal for transplantation. FTY720 is a synthetic drug that modulates immune responses of transplantation in many animal models. FTY720 modulating mechanisms relate to lymphocyte migration to peripheral lymph nodes instead of inflammatory sites. The drug has no effect on T-cell proliferation or cytokine production, and therefore prevents generalized immunosuppression. However, it is still to be confirmed that FTY720 has no nephrotoxic effects when administered continuously. In the present study FTY720 was administered orally for 21 days to C57BL/6 mice that underwent weekly evaluations. FTY720 (1 mg/kg per day) impaired body weight gain, but had no significant effect on either renal function or structure. Our findings suggest that FTY720 may provide a reasonable add-on therapy in calcineurin-inhibitor-treated transplant recipients.
引用
收藏
页码:112 / 113
页数:2
相关论文
共 13 条
  • [1] The membrane attack complex, C5b-9, up regulates collagen gene expression in renal tubular epithelial cells
    Abe, K
    Li, K
    Sacks, SH
    Sheerin, NS
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 136 (01) : 60 - 66
  • [2] THERAPEUTIC ADVANTAGE OF CONVERTING ENZYME-INHIBITORS IN ARRESTING PROGRESSIVE RENAL-DISEASE ASSOCIATED WITH SYSTEMIC HYPERTENSION IN THE RAT
    ANDERSON, S
    RENNKE, HG
    BRENNER, BM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (06) : 1993 - 2000
  • [3] FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation
    Brinkmann, V
    Pinschewer, D
    Chiba, K
    Feng, LL
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (02) : 49 - 52
  • [4] Chiba K, 1996, TRANSPLANT P, V28, P1056
  • [5] Chiba K, 1998, J IMMUNOL, V160, P5037
  • [6] Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: A multicenter, randomized, placebo-controlled, phase I study
    Kahan, BD
    Karlix, JL
    Ferguson, RM
    Leichtman, AB
    Mulgaonkar, S
    Gonwa, TA
    Skerjanec, A
    Schmouder, RL
    Chodoff, L
    [J]. TRANSPLANTATION, 2003, 76 (07) : 1079 - 1084
  • [7] FTY720 treatment prolongs skin graft survival in a completely incompatible strain combination
    Lima, RSM
    Nogueira-Martins, MF
    Silva, HT
    Pestana, JOM
    Bueno, V
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (04) : 1015 - 1017
  • [8] Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice
    Maki, T
    Gottschalk, R
    Monaco, AP
    [J]. TRANSPLANTATION, 2002, 74 (12) : 1684 - 1686
  • [9] Evaluation of laser Doppler flowmetry to assess cyclosporine A-induced impairment of renal blood flow
    Naef, M
    Baer, HU
    Glaser, C
    Wheatley, AM
    Schilling, MK
    Seiler, CA
    Büchler, MW
    [J]. JOURNAL OF SURGICAL RESEARCH, 1998, 75 (02) : 161 - 164
  • [10] FTY720 impairs necrosis development after ischemia-reperfusion injury
    Oliveira, CMS
    Borra, RC
    Franco, M
    Schor, N
    Silva, HT
    Pestana, JOM
    Bueno, V
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (04) : 854 - 856